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Abstract
Background: The computerisation of primary health care (PHC) records offers the opportunity to focus on pharmacy 
expenditure from the perspective of the morbidity of individuals. The objective of the present study was to analyse the 
behaviour of pharmacy expenditure within different morbidity groups. We paid special attention to the identification 
of individuals who had higher values of pharmacy expenditure than their morbidity would otherwise suggest (i.e. 
outliers).
Methods: Observational study consisting of 75,574 patients seen at PHC centres in Zaragoza, Spain, at least once in 
2005. Demographic and disease variables were analysed (ACG® 8.1), together with a response variable that we termed 
'total pharmacy expenditure per patient'. Outlier patients were identified based on boxplot methods, adjusted boxplot 
for asymmetric distributions, and by analysing standardised residuals of tobit regression models.
Results: The pharmacy expenditure of up to 7% of attendees in the studied PHC centres during one year exceeded 
expectations given their morbidity burden. This group of patients was responsible for up to 24% of the total annual 
pharmacy expenditure. There was a significantly higher number of outlier patients within the low-morbidity band 
which matched up with the higher variation coefficient observed in this group (3.2 vs. 2.0 and 1.3 in the moderate- and 
high-morbidity bands, respectively).
Conclusions: With appropriate validation, the methodologies of the present study could be incorporated in the 
routine monitoring of the prescribing profile of general practitioners. This could not only enable evaluation of their 
performance, but also target groups of outlier patients and foster analyses of the causes of unusually high pharmacy 
expenditures among them. This interpretation of pharmacy expenditure gives new clues for the efficiency in utilisation 
of healthcare resources, and could be complementary to management interventions focused on individuals with a 
high morbidity burden.
Background
Analyses of trends in pharmacy expenditures are fre-
quently carried out from a population perspective, focus-
ing on the gross increase in costs [1,2]. However, the
computerisation of primary health care (PHC) records
and the resulting large databases offer an excellent oppor-
tunity to address this problem considering the health
characteristics of individual patients [3] such as the type
and burden of morbidity [4].
The development of patient classification systems has
enabled measurement and profiling the morbidity of
patients and populations according to their complexity
and expected utilisation of healthcare resources [5]. That
is, patients with similar morbidity profiles are likely to
require equal delivery of healthcare resources (e.g. pre-
scriptions). The Adjusted Clinical Groups (ACGs) system
developed at Johns Hopkins University (Baltimore, MD,
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Page 2 of 8USA) is considered to offer great potential within PHC
due to its holistic and longitudinal approach in charac-
terising the morbidity burden of patients as well as its
capacity to describe the case-mix of a reference popula-
tion [6,7]. The commonest applications of ACGs com-
prise assessment of provider performance, allocation and
utilisation of resources, and outcomes analyses [8,9].
When analysing pharmacy expenditure, the tools men-
tioned above can also be used to study the behaviour of
expenditure within the different categories of health sta-
tus. Further, focusing on individuals whose expenditure is
higher than the average within one specific category of
health status seems to be of particular interest. This
group of individuals, statistically named as 'outliers' [10],
can also be understood as those whose pharmacy expen-
ditures exceed their burden of morbidity. This new
approach is important: (i) for identifying patients for
whom pharmacy care and its potential cost may be opti-
mised; and (ii) because it opens up new research channels
related to the characterization and prediction of patients
and professionals on whom cost-control measures should
be focused.
The objective of the present study was to analyse the
behaviour of pharmacy expenditure within different mor-
bidity groups. We paid special attention to the identifica-
tion of individuals who had higher expenditure values
than their morbidity would otherwise suggest.
Methods
A retrospective observational study was conducted based
on information provided by computerised clinical
records from six PHC centres in Zaragoza, Spain, in 2005.
In an effort to obtain a homogeneous sample with respect
to the quality of the records, we only selected centers with
≥ 2 years of experience in the use of computerised clinical
records (as compiled through the OMI-AP system). We
only included patients aged > 14 years who had been
assigned to these centres and who attended such centres
at least once during the study year. The final study popu-
lation was composed of 75,574 patients.
Data were obtained from administrative registries of
the Aragon Health Care System (Zaragoza, Spain) after
official request and authorization. Personal information
was made anonymous according to the Spanish Organic
Law of Personal Data Protection 15/1999. This work was
part of a project funded by the Carlos III Health Institute,
which was approved by the Ethics Committee for Clinical
Investigation of Aragon (CEICA).
Study variables
Demographic variables (age, sex), pharmacy expenditure,
and burden of morbidity were recorded for each patient.
For the latter, all diagnoses or reasons for visits assigned
to each patient during the study period were coded
according to the International PHC Classification
(IPHCC) [11]. Subsequent conversion ('mapping') was
made from the IPHCC to the International Disease Clas-
sification (ICD-9-CM) [12].
Based on the variables of age, sex and diagnosis regis-
tered along the study year, a single ACG category was
assigned to each patient [13]. The ACG system (version
8.1®) assigns all ICD-9-CM codes to one of 34 diagnosis
clusters known as 'Aggregated Diagnosis Codes' (ADGs).
Individual diseases or conditions are placed into a single
ADG cluster based on the: duration of the condition (e.g.
acute, recurrent, or chronic); severity of the condition
(e.g. minor and stable versus major and unstable); diag-
nostic certainty (symptoms versus documented disease),
aetiology of the condition (infectious, injury, or other);
and specialty care involvement (e.g. medical, surgical,
obstetric, haematologic). Each ADG is a grouping of diag-
nosis codes that are similar in terms of severity and likeli-
hood of persistence of the health condition treated over a
relevant period of time. In a second stage, the ACG meth-
odology uses a branching algorithm to place subjects into
one of 106 discrete categories based on their assigned
ADGs, their age, and their sex. The result is that individu-
als within a given ACG have experienced a similar pattern
of morbidity and resource utilisation over a given year.
For the sake of parsimony, ACGs with similar expected
use of resources are aggregated into 'morbidity bands' (i.e.
low, moderate or high).
The primary measurement variable, which we termed
'total pharmacy expenditure per patient', included the
retail price of medicines, supplies and accessories con-
sumed by patients. This was obtained by combining data
between the billing database of the pharmacy offices and
the OMI-AP patient database. The tables were cross-ref-
erenced via the health card identifier (a sequential
numeric tag assigned to each patient). All identifying data
were removed to guarantee confidentiality.
Identification of outlier patients
There are many statistical procedures for identifying out-
lier data. Most are designed to prevent a 'masking' effect
by groups of outliers or to be applied with multivariate
data [14]. The aim of the present study was to identify
subgroups of 'unusual' patients in terms of their phar-
macy expenditure considering their morbidity burden
given the absence of a well-defined external cutoff, rather
than the deletion of suspicious data or a robust estima-
tion of location or scale parameters. The applied methods
were chosen on the basis of a balanced compromise
between their simplicity and their adequacy to the nature
of the dependent variable 'pharmacy expenditure'. The
statistical procedures for identifying outlier data are
detailed below.
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One of the most frequently used graphical techniques for
visualising the distribution of continuous univariate data
is the boxplot, which was originally proposed by Tukey
[15]. This tool gives information about the location,
spread, skewness and tails of data. This last application
consists of detecting the atypical cases of a distribution
based on the following formula:
where Q3i and Q1i are quartiles three and one, respec-
tively, of the distribution of pharmacy expenditure for
each ACG. Patients whose spending during the study
period exceeded the trimming point (Ti) respective to
their ACG category were considered to be outliers.
The constant 1.5 is the commonest value applied in
Boxplot techniques. It is widely acknowledged that 0.35%
of normally distributed data exceeds the trimming point
(Ti) for moderate sample sizes (rate of false-positives).
This percentage can be highly increased in non-normal
or asymmetric distributions.
(ii) Adjusted boxplot for asymmetric distributions and 
stratified by ACG (Adj. BXP)
For asymmetric distributions (as is the case for pharmacy
expenditures), the BXP method tends to identify too
many extreme cases (outliers) because the trimming
points are derived from a normal distribution [16]. In
these cases, Hubert et al. [17] proposed a generalisation
of the boxplot that includes a robust asymmetry mea-
surement to determine the trimming limits or points,
which they called function hr (Medcouple, MC). The med-
couple is defined as:
where x1 and x2 are independently sampled cases of the
asymmetric distribution F, mF is the median of F, and h is
the kernel function given by the following formula:
Thus, the upper limit of the intervals is given by:
According to this same study, the family of exponential
models should be chosen to generalise function hr (MC).
(iii) Standardised residuals (RESID)
Another method for detecting individuals with atypical
values in the dependent variable (Y) and which is widely
used for regression model diagnostics is the residual anal-
ysis:
where yi are the observed values and  the predicted
values of Y.
Standardization of these residuals is applied to elimi-
nate the effect of the measurement units on account of
the dependent variable [18]. If the normality assumption
is fulfilled, the percentage of standardised residuals that
fall out of the interval ± 2 is ~5%. Thus, cases with a
residual > 2 are considered 'extreme' and therefore identi-
fied as outliers [19].
Regarding the regression model, the logarithm of phar-
macy expenditure was used as the dependent variable to
standardise the distribution [20]. The independent 'ACG
category' variable was introduced into the model as a
group of dummy variables. The 'pharmacy expenditure'
interest variable had a truncation point in the nil expen-
diture (7.8% of the population recorded nil expenditure),
so truncated tobit models were applied [21]. In these
cases, the distribution of the variable in question is mod-
elled as a mixture of a continuous distribution and a dis-
crete distribution [22].
Demographic, clinical, and pharmacy-expenditure 
characteristics of outlier patients
A descriptive analysis was first carried out on a global
basis and for each group of patients (normal/outliers)
whereby the mean, median, and variation coefficient of
the continuous variables and the distribution of frequen-
cies of the categorical variables were calculated. The dif-
ferences between outlier patients and the rest were
analysed as well as the differences between outlier groups
themselves (dependent upon the applied identification
method) via the Mann-Whitney U test if the variable was
continuous but did not follow a normal distribution (age,
mean annual expenditure per patient, and mean annual
number of visits per patient) and by a chi-square test for
the qualitative sex and morbidity burden variables. Later,
a residual study for these latter variables was undertaken
in the event of significant differences.
Given the large sample size, interpreting differences in
terms of statistical significance would lead to misinter-
pretations. Evaluation of the relevance and magnitude of
the differences between normal and outlier patients and
among outlier groups themselves was carried out based
on 'comparison indices' (Table 1). Calculation of these
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population as a reference. Based on this information, we
calculated three ratios. First, we calculated the 'observed/
average' ratio. This divides the annual average expendi-
ture per patient in each specific group by the annual aver-
age expenditure per patient within the general
population. This indicates the extent to which a certain
group of patients has a higher expenditure relative to the
general mean. Second, we calculated the 'expected/aver-
age' ratio. Bearing in mind the burden of morbidity, this
ratio divides the expected expenditure for each specific
group by the expenditure of the general population. From
this we deduce the degree to which a certain subgroup of
the population exhibits a higher or lower burden of mor-
bidity than the mean of the general population. Third, we
calculated the 'observed/expected' ratio. This ratio
Table 1: Demographic, clinical, and pharmacy-expenditure characteristics of outlier patients according to the 
identification method (n = 75,574).
General 
population
Patients with normal pharmacy expenditure Outliers
BXP Adj. BXP RESID BXP Adj. BXP RESID
Demographic characteristics
Average age 49.3 49.2a 49.3a 49.3a 50.3abc 48.01ab 47.5ac
Women (%) 55.8 55.8 55.8 55.9a 56.3bc 56.5bd 51.0acd
Patient proportion 
(%)





413.1 334.7a 376.4a 388.19a 1,548.2abc 2,509.2abd 2,434.3acd
Proportion of total 
expenditure (%)
100 75.8 89.6 92.8 24.2 10.4 7.2
Morbidity bands
Low (%) 22.3 21.7a 22.0a 22.0a 30.5abc 34.7abd 39.2acd
Moderate (%) 57.9 57.7a 58.0a 57.9a 59.6abc 53.0abd 55.6acd




1 0.8 0.9 0.9 3.8 6.1 5.9
Expected/Average 1 1.1 1.1 1.1 0.7 0.6 0.4
Observed/
Expected
1 0.7 0.8 0.9 5.4 10.1 13.3
The p-value corresponds to the chi-square test in the case of percentages or to the Mann-Whitney U test for continuous variables:
a Significant differences between normal and outlier patients (p < 0.05)
b Significant differences between outlier patients identified by BXP and Adj. BXP (p < 0.05)
c Significant differences between outlier patients identified by BXP and RESID (p < 0.05)
d Significant differences between outlier patients identified by Adj.BXP and RESID (p < 0.05)
The associations between the morbidity bands and the type of patient were calculated by analysing standardised residuals of the chi-square 
test:
BOLD TEXT Significant association between categories (p < 0.05)
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observed in each specific group by the annual average
expenditure per patient expected in those same groups
given the burden of morbidity. This indicates the mean
expenditure of each subgroup of patients compared with
the mean expenditure of the general population, adjust-
ing for morbidity.
The STATA 10 software package was used to calculate
the truncated tobit models, R free software to calculate
function hr (Medcouple, MC) and SPSS 15.0 for the
remainder of our statistical analyses.
Results
The general population (n = 75,574) was composed of
55.8% women with an average age of 49.3 years (confi-
dence interval (CI) 95% 49.1-49.4). More than one-quar-
ter of the population was aged > 64 years, and 66.9% of
the assigned population of the centre attended during the
study year. The population was grouped in 67 ACGs con-
sisting of an average of 1128 individuals. The standard
deviation of pharmacy expenditure within ACGs was
very heterogeneous, ranging from 58.3€ up to 2919.0€.
The variation coefficients by ACGs ranged from 0.9 to 6.6
(mean, 2.6). The variability observed within the morbid-
ity bands is summarised in Table 2.
Comparisons between normal patients and outlier patients 
with regard to the annual pharmacy expenditure
There were statistically significant differences between
normal patients and outlier patients (regardless of the
method used to identify these groups). This is corrobo-
rated by the observed/average ratios which, for this
group, suggested pharmacy expenditures 3.8-6.1-times
greater than the global mean (Table 1, observed/average
ratios). The analysis of the standardised residuals of the
chi-square test indicated that there was a significantly
higher presence of outlier patients within the low-mor-
bidity band which matched up with the higher variation
coefficient observed in this group (3.2 vs. 2.0 and 1.3 in
the moderate- and high-morbidity bands, respectively).
The expected/average ratio showed that the outlier popu-
lation was 30-60% less ill than the general reference pop-
ulation (Table 1, expected/average ratios). As a result, the
observed/expected ratios were 5-13-times greater for
outlier patients than for patients with a normal expendi-
ture (Table 1, observed/expected ratios).
Comparisons between groups of outlier patients 
dependent upon the identification method
The first noticeable finding was the difference in the
number of patients detected by each method. Whereas
the BXP method detected 6.5% of the population, the Adj.
BXP and RESID methods detected 1.7% and 1.2%, respec-
tively (Table 1). Second, these last two methods detected
subpopulations of the group that was detected by the
BXP method (Figure 1). Third, patients detected by the
Adj. BXP and RESID methods had expenditures 800-
1000€ higher per year than patients detected by the BXP
method. These differences were statistically significant
and became evident in the observed/average ratios (Table
1, observed/average ratios). Figure 2 emphasizes these
differences, also illustrating increasing differences by age.
A detailed analysis of the different burdens of morbidity
among these three groups of patients reveals that patients
detected by the Adj. BXP and RESID methods were 10-
30% less sick than the population identified by the BXP
method (Table 1, expected/average ratios). Fourth, differ-
ences were noticed in the 'proportion of total expendi-
ture/patient proportion' ratios for the BXP method and
the Adj. BXP and RESID methods (ratios 3.7; 6.1 and 6.0,
respectively). The ratios between the observed and
expected expenditure as detected by the Adj. BXP and
RESID methods were almost twofold greater than that for
the BXP method (Table 1, observed/expected ratios).
Discussion
The results of the present study indicated that pharmacy
expenditure of up to 7% of the population attending the
studied PHC centres during one year exceeded expecta-
tions given their morbidity burden, and that this group of
patients was responsible for up to 24% of the total annual
pharmacy expenditure. This information may be of inter-





Mean (€) Std. Dev. (€) VC Min-Max (€) Median (€) Q1-Q3 (€)
Low 16,818 75.1 238.61 3.2 0.0-9,110.8 15.4 3.5-45.7
Moderate 43,453 383.7 779.14 2.0 0.0-35,993.1 109.0 25.3-469.8
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in pharmacy expenditures in PHCs, and the application
of possible measures for efficient and rational manage-
ment of drug prescriptions.
Among the existing pharmacy cost-containment poli-
cies in Europe, some are focused on one of the key stake-
holders in healthcare: the prescriber. This is achieved
through the analysis of the quality and costs of their pre-
scribing [23]. Several countries disseminate reviews of
drug utilisation to general practitioners (GPs) on the
basis that prompt, detailed feedback of individualised
prescribing data may be effective in rationalising the use
of drugs [24]. The concepts and methodologies shown in
the present study could be incorporated in the routine
monitoring of the prescribing profile of GPs. This could
be used to evaluate not only their performance, but also
to target groups of outlier patients and foster analyses of
the causes of unusual pharmacy expenditures among
them, thereby furthering the design of specific interven-
tions.
The results of the present study indicate that there was
a potential margin to improve drug utilisation in the
group of patients with a low morbidity burden. That is,
there was a lower correspondence between the morbidity
profile of patients and their expenditure in those groups
of patients who showed a low morbidity burden. A wider
variation of pharmacy expenditure was observed within
the group of patients with a low morbidity burden (varia-
tion coefficient: 3.2 vs. 2.0 and 1.3 in the moderate- and
high-morbidity bands, respectively), leading to a higher
number of patients whose figures were far removed from
the expenditure of most patients belonging to the same
group (i.e. outliers). The expenditure of this group of out-
liers was up to 13-times higher than expected given their
burden of morbidity. This interpretation of pharmacy
expenditure gives new clues for the efficiency in utilisa-
tion of healthcare resources, and could be complemen-
tary to management interventions focused on individuals
with a high morbidity burden [25,26].
The trimming methods of the present study have been
widely applied in the hospital setting to avoid incorporat-
Figure 1 Overlapping subsets among outlier populations as de-
tected by three statistical methods.
Figure 2 Differences in pharmacy expenditure of outlier patients relative to the mean expenditure expected for each ACG category, by age 
groups.
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resources of a given healthcare resource group [27,28].
However, analysing the group of outliers itself deserves
special attention. All three methods are easy to imple-
ment, adjusted by morbidity burden and adapted to the
large sample size and the non-parametric distribution of
the studied variable pharmacy expenditure, which is why
other tests (e.g. Grubbs' test, Dixon's Q test) were not
used. The three methodologies identify subgroups of the
same population, reinforcing the robustness of the
selected techniques. However, which method best identi-
fies the group of outlier patients? The empirical evidence
suggests that the most sophisticated statistical methods,
such as the Adj. BXP for asymmetric distributions or
standardised residuals, offer more specificity in identify-
ing outlier patients. The average expenditure of patients
detected by these two methods was 800-1000€ higher per
year than that of patients detected by the classic BXP
method. Moreover, these expenditures had a lower corre-
spondence with their burden of morbidity as reflected in
the ratios between the observed and expected expendi-
ture, which were almost twofold greater than that given
by the classic BXP method.
According to the World Health Organisation, the ratio-
nal use of drugs requires that patients receive medica-
tions appropriate to their clinical needs at the lowest cost
to them and their community. The evidence indicates
that there may be factors associated to the practitioner
and the patient which deviate them from the rational use
of drugs, resulting in an unjustifiable use of scarce
resources and widespread health hazards. Among the
variables related to the practitioner, the continuous train-
ing, the influence of the pharmaceutical industry, and the
'burnout syndrome' as a consequence of chronic stress at
the workplace have been identified most frequently [29].
Regarding patient-related factors, the pressure that they
can occasionally exert to obtain medications that 'cure'
their health problem has been discussed [30,31]. This
problem is aggravated when practitioners' time to see a
patient is limited [32]. The pressure can be very difficult
to handle because, in most cases, there is little time to
explain the preferred treatment option of GPs to sceptical
patients [33].
These findings must be interpreted with caution due to
several reasons that may affect their internal and external
validity. The main potential limiting factor of the present
study could be related to the quality of the diagnostic
information registered in the electronic medical records.
Even if a series of inclusion criteria were applied during
the health centre selection process to guarantee the qual-
ity and reliability of clinical data, a two-year period of
experience in the use of electronic records may be insuffi-
cient. This could explain why patients have pharmacy
expenditures for diseases that are not registered in the
medical records of GPs, thus over-estimating the lack of
correspondence between expenditure and morbidity bur-
den of the population. Using more recent data is required
to confirm the internal validity of the results.
Second, there were limitations derived from the study
design owing to the restricted access to information. That
is, drug use was evaluated only in terms of the expendi-
ture. This ignored aspects related to the number of drug
prescriptions or the number of defined daily doses. This
variable would have been of great help when analysing
the causes of excess use of drugs within the same morbid-
ity group.
A third factor that could compromise the internal valid-
ity of the results obtained in the present study was related
to the explanatory capacity of the tool used to measure
morbidity: ACGs. It could be argued that the ACGs per-
form weakly in low-morbidity bands or, further, that
updates on the effectiveness and cost-effectiveness of
health technologies (e.g. drugs) were not considered in
the design process. Nevertheless, the statistical power of
the ACG system developed at Johns Hopkins University
has been internationally validated [34-37] and its differ-
ent versions are regularly updated [13].
Fourth, the results of the present study correspond to a
population treated in urban health centres. They are
therefore not fully representative of the population
treated across an entire health system at the PHC level,
thus affecting their external validity. Nevertheless, the
characteristics of the studied sample, such as the average
number of diagnoses per patient [38], the intensity of use
[5,39], the proportion of women, the aging rate, and the
distribution of patients according to ACGs [40] fit in with
those reported in national and international studies.
If the methodology of the present study is to be used to
target patients and prescribers amenable to intervention
strategies, they should first be validated. This implies a
clinical validation by expert panels as well as carrying out
economic studies that shed light on the potential savings
of this type of interventions.
Conclusions
We began this contribution by asking if the pharmacy
expenditure of patients always corresponds with their
morbidity burden. The present study identified a group of
patients with low morbidity whose pharmacy expendi-
ture exceeded expectations. Identification of the factors
that influence this excess in pharmacy expenditure can
improve the adaptation of pharmacy services and
increase the efficiency of the PHC system.
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